Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option

Author(s): Taylor Bramblett, Mohamed Teleb*, Aymen Albaghdadi, Harsh Agrawal, Debabrata Mukherjee

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Volume 17 , Issue 2 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Background: Heart failure with preserved ejection fraction (HFpEF) makes up half of diagnosed heart failure (HF) cases and has similar outcomes compared to heart failure with reduced ejection fraction (HFrEF) but a discrepancy in knowledge and approach to treatment. HFpEF is diagnosed using the following criteria: symptoms, preserved ejection fraction (greater than 50%), and evidence of abnormal left ventricular filling or relaxation, or diastolic distensibility or stiffness. Studies conducted to examine the efficacy of angiotensin receptor blockers (ARB) (irbesartan and candesartan), thiazide diuretics (chlorthalidone), and angiotensin converting enzyme inhibitors (ACEI) (perindopril) in the treatment of HFpEF, showed moderate efficacy but no clear benefit. Recently, the FDA has approved a novel drug, which combines an angiotensin receptor neprilysin inhibitor and ARB (valsartan) named LCZ696 (entresto) for possible treatment of HFrEF.

Conclusion: In this article, we will discuss the failure of previous treatment modalities and the promise that LCZ696 (entresto) may hold for treating patients with HFpEF.

Keywords: Heart failure, LCZ696, entresto, preserved ejection fraction, vasodilation, diuresis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [80 - 85]
Pages: 6
DOI: 10.2174/1871529X17666170703120237
Price: $65

Article Metrics

PDF: 91